Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 107

1.

Impact of patient and disease characteristics on therapeutic success during adalimumab treatment of patients with rheumatoid arthritis: data from a German noninterventional observational study.

Kleinert S, Tony HP, Krause A, Feuchtenberger M, Wassenberg S, Richter C, Röther E, Spieler W, Gnann H, Wittig BM.

Rheumatol Int. 2012 Sep;32(9):2759-67. doi: 10.1007/s00296-011-2033-5. Epub 2011 Aug 6.

2.

Reduction in sickness absence in patients with rheumatoid arthritis receiving adalimumab: data from a German noninterventional study.

Krüger K, Wollenhaupt J, Lorenz HM, Röther E, Wittig BM.

Rheumatol Int. 2012 Dec;32(12):3977-83. doi: 10.1007/s00296-011-2317-9. Epub 2011 Dec 30.

PMID:
22207197
3.

The impact of prior biologic therapy on adalimumab response in patients with rheumatoid arthritis.

Feuchtenberger M, Kleinert S, Scharbatke EC, Gnann H, Behrens F, Wittig BM, Greger G, Tony HP.

Clin Exp Rheumatol. 2015 May-Jun;33(3):321-9. Epub 2015 Apr 14.

PMID:
25897681
4.

Development and validation of a new disease activity score in 28 joints-based treatment response criterion for rheumatoid arthritis.

Behrens F, Tony HP, Alten R, Kleinert S, Scharbatke EC, Köhm M, Gnann H, Tams J, Greger G, Burkhardt H.

Arthritis Care Res (Hoboken). 2013 Oct;65(10):1608-16. doi: 10.1002/acr.22037.

5.

Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry.

Hetland ML, Christensen IJ, Tarp U, Dreyer L, Hansen A, Hansen IT, Kollerup G, Linde L, Lindegaard HM, Poulsen UE, Schlemmer A, Jensen DV, Jensen S, Hostenkamp G, Østergaard M; All Departments of Rheumatology in Denmark..

Arthritis Rheum. 2010 Jan;62(1):22-32. doi: 10.1002/art.27227.

6.

B cell depletion may be more effective than switching to an alternative anti-tumor necrosis factor agent in rheumatoid arthritis patients with inadequate response to anti-tumor necrosis factor agents.

Finckh A, Ciurea A, Brulhart L, Kyburz D, Möller B, Dehler S, Revaz S, Dudler J, Gabay C; Physicians of the Swiss Clinical Quality Management Program for Rheumatoid Arthritis..

Arthritis Rheum. 2007 May;56(5):1417-23.

7.

Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.

Hyrich KL, Watson KD, Silman AJ, Symmons DP; British Society for Rheumatology Biologics Register..

Rheumatology (Oxford). 2006 Dec;45(12):1558-65. Epub 2006 May 16.

PMID:
16705046
8.

Adalimumab in clinical practice. Outcome in 70 rheumatoid arthritis patients, including comparison of patients with and without previous anti-TNF exposure.

Bennett AN, Peterson P, Zain A, Grumley J, Panayi G, Kirkham B.

Rheumatology (Oxford). 2005 Aug;44(8):1026-31. Epub 2005 May 3.

PMID:
15870150
9.

Adalimumab and methotrexate is more effective than adalimumab alone in patients with established rheumatoid arthritis: results from a 6-month longitudinal, observational, multicentre study.

Heiberg MS, Rødevand E, Mikkelsen K, Kaufmann C, Didriksen A, Mowinckel P, Kvien TK.

Ann Rheum Dis. 2006 Oct;65(10):1379-83. Epub 2006 May 5.

10.

Persistent periodontal disease hampers anti-tumor necrosis factor treatment response in rheumatoid arthritis.

Savioli C, Ribeiro AC, Fabri GM, Calich AL, Carvalho J, Silva CA, Viana VS, Bonfá E, Siqueira JT.

J Clin Rheumatol. 2012 Jun;18(4):180-4. doi: 10.1097/RHU.0b013e31825828be.

PMID:
22647860
11.

Anti-infliximab and anti-adalimumab antibodies in relation to response to adalimumab in infliximab switchers and anti-tumour necrosis factor naive patients: a cohort study.

Bartelds GM, Wijbrandts CA, Nurmohamed MT, Stapel S, Lems WF, Aarden L, Dijkmans BA, Tak PP, Wolbink GJ.

Ann Rheum Dis. 2010 May;69(5):817-21. doi: 10.1136/ard.2009.112847. Epub 2009 Jul 5.

PMID:
19581278
12.
13.

Predictors of response to anti-TNF therapy according to ACR and EULAR criteria in patients with established RA: results from the South Swedish Arthritis Treatment Group Register.

Kristensen LE, Kapetanovic MC, Gülfe A, Söderlin M, Saxne T, Geborek P.

Rheumatology (Oxford). 2008 Apr;47(4):495-9. doi: 10.1093/rheumatology/ken002. Epub 2008 Mar 3.

PMID:
18316338
14.

Effectiveness of adalimumab for rheumatoid arthritis in patients with a history of TNF-antagonist therapy in clinical practice.

Bombardieri S, Ruiz AA, Fardellone P, Geusens P, McKenna F, Unnebrink K, Oezer U, Kary S, Kupper H, Burmester GR; Research in Active Rheumatoid Arthritis (ReAct) Study Group..

Rheumatology (Oxford). 2007 Jul;46(7):1191-9. Epub 2007 May 15.

PMID:
17504821
15.
16.

Outcomes of switching anti-TNF drugs in rheumatoid arthritis--a study based on observational data from the Finnish Register of Biological Treatment (ROB-FIN).

Virkki LM, Valleala H, Takakubo Y, Vuotila J, Relas H, Komulainen R, Koivuniemi R, Yli-Kerttula U, Mali M, Sihvonen S, Krogerus ML, Jukka E, Nyrhinen S, Konttinen YT, Nordström DC.

Clin Rheumatol. 2011 Nov;30(11):1447-54. doi: 10.1007/s10067-011-1779-1. Epub 2011 Jun 7.

PMID:
21644062
17.

Comparison of long-term clinical outcome with etanercept treatment and adalimumab treatment of rheumatoid arthritis with respect to immunogenicity.

Krieckaert CL, Jamnitski A, Nurmohamed MT, Kostense PJ, Boers M, Wolbink G.

Arthritis Rheum. 2012 Dec;64(12):3850-5. doi: 10.1002/art.34680.

18.

Clinical remission and/or minimal disease activity in patients receiving adalimumab treatment in a multinational, open-label, twelve-week study.

Burmester GR, Ferraccioli G, Flipo RM, Monteagudo-Sáez I, Unnebrink K, Kary S, Kupper H.

Arthritis Rheum. 2008 Jan 15;59(1):32-41. doi: 10.1002/art.23247.

19.

TNFα antagonist therapy does not increase the Epstein-Barr virus burden in patients with rheumatoid arthritis or ankylosing spondylitis.

Couderc M, Payet S, Henquell C, Dubost JJ, Soubrier M.

Joint Bone Spine. 2010 Oct;77(5):414-7. doi: 10.1016/j.jbspin.2010.04.014. Epub 2010 Jun 9.

PMID:
20542718
20.

Effectiveness of rituximab in patients with rheumatoid arthritis: observational study from the British Society for Rheumatology Biologics Register.

Soliman MM, Hyrich KL, Lunt M, Watson KD, Symmons DP, Ashcroft DM; British Society for Rheumatology Biologics Register..

J Rheumatol. 2012 Feb;39(2):240-6. doi: 10.3899/jrheum.110610. Epub 2011 Dec 15.

Supplemental Content

Support Center